Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AJ302-IM Phase 1 single ascending dose study in healthy volunteers
NCT06625541Phase 1Completed
- Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing AJ302-IM with Placebo (2 arms). Primary endpoint: Adverse Events at 57 days. Started Jun 2024; status: completed.
02
Drugs
AJ302
Beyond the preview
Go deeper on NCT06625541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625541.